Key Points
- Bryan Ball sold 6,596 shares of Whitehawk Therapeutics on April 10 at an average price of $3.43 (totaling $22,624), a transaction disclosed to the SEC and made to cover tax withholding from vested equity; he now directly owns 515,955 shares, a 1.26% reduction in his stake.
- Whitehawk shares opened at $3.47 (market cap ~$163.8M) and the company recently beat quarterly EPS estimates (‑$0.34 vs. ‑$0.55), but analyst coverage is mixed with an average "Hold" rating and a consensus price target of $6.50.
- Ball has made additional recent sales, including 50,000 shares on April 9 at $3.57 ($178,500) and 1,834 shares on March 2 at $3.31, signaling a pattern of insider dispositions in the period.
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) insider Bryan Ball sold 6,596 shares of the stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $3.43, for a total transaction of $22,624.28. Following the completion of the transaction, the insider directly owned 515,955 shares of the company's stock, valued at $1,769,725.65. The trade was a 1.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Bryan Ball also recently made the following trade(s):
- On Thursday, April 9th, Bryan Ball sold 50,000 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.57, for a total transaction of $178,500.00.
- On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total transaction of $6,070.54.
Whitehawk Therapeutics Stock Up 2.4%
Shares of Whitehawk Therapeutics stock opened at $3.47 on Tuesday. The firm has a market capitalization of $163.78 million, a P/E ratio of 7.38 and a beta of 0.57. The company has a 50 day moving average price of $3.36 and a 200 day moving average price of $2.73. Whitehawk Therapeutics, Inc. has a 52 week low of $1.39 and a 52 week high of $4.48.
Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.21.
Hedge Funds Weigh In On Whitehawk Therapeutics
Institutional investors have recently bought and sold shares of the business. Quadrature Capital Ltd purchased a new position in Whitehawk Therapeutics during the 4th quarter worth approximately $28,000. ABG Innovation Capital Partners III GP Ltd purchased a new position in Whitehawk Therapeutics during the 3rd quarter worth approximately $51,000. Dimensional Fund Advisors LP purchased a new position in Whitehawk Therapeutics during the 3rd quarter worth approximately $84,000. Marshall Wace LLP purchased a new position in Whitehawk Therapeutics during the 4th quarter worth approximately $164,000. Finally, Jane Street Group LLC raised its position in Whitehawk Therapeutics by 177.3% during the 4th quarter. Jane Street Group LLC now owns 69,931 shares of the company's stock worth $169,000 after buying an additional 44,716 shares during the last quarter. 52.08% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
WHWK has been the subject of several research analyst reports. JonesTrading initiated coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They issued a "buy" rating and a $7.00 price objective for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Oppenheimer initiated coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They issued an "outperform" rating and a $6.00 price objective for the company. Finally, Wall Street Zen lowered shares of Whitehawk Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Whitehawk Therapeutics has an average rating of "Hold" and a consensus price target of $6.50.
Check Out Our Latest Stock Report on Whitehawk Therapeutics
About Whitehawk Therapeutics
(
Get Free Report)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
